ALTO-101 is an investigational phosphodiesterase-4 (PDE4) inhibitor delivered via a transdermal patch. Inhibition of the PDE4 enzyme is expected to enhance neural circuits and improve cognitive ...
Approved for MDD in 2018, iTBS is a quicker form of repetitive transcranial magnetic stimulation (rTMS), with sessions averaging 3 minutes as compared with 40 minutes for traditional rTMS sessions -- ...
First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications ...
ADHD affects millions across the lifespan, disrupting school, work and relationships. Once seen as a childhood disorder, it’s ...
Early research suggests a brain test may predict whether antidepressants will cause sexual dysfunction. There has never been ...
Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical ...
Researchers say the experimental tool has huge implications for public health, especially in conjunction with Alzheimer’s drugs that are most effective in the disease’s early stages ...
Doctors need reliable ways to predict seizure risk after a first unprovoked seizure, to help guide diagnosis and treatment. This is especially important because a diagnosis of epilepsy can now be made ...
ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophreniaEncouraging trends observed in ...
The debut solo London exhibition by artist and writer Morgan Quaintance, Available Light opens at UAL's Chelsea Space, near ...
“Future research will help clarify whether long-term music practice can strengthen the brain’s ability to process rhythm ...